INFOGRAPHIC: Mental Health; A Road Still Less Travelled By Pharma
The scope of mental disorders and increasing patient numbers represent opportunity for pharma and biotech, but historically these conditions have carried high risk/low success rate labels. As the number of patients continues to grow with the world's expanding and aging population, voids in available drug treatments for some conditions will become more apparent.
You may also be interested in...
Alkermes’s announcement of positive findings in the FORWARD-5 trial of its treatment-resistant depression drug ALKS 5461 came as a surprise, given the past two Phase III trials disappointed, but if it can gain approval, the buprenorphine/samidorphan product could meet an unmet need.
The unexpected failure of a Phase III trial of Intra-Cellular Therapies’ lead product ITI-007 sent shares in the company down by more than 63%.
The private company may be behind the leaders, but with a long-term plan and a strategy of coming in with complementary therapies like the 5-HT6 receptor antagonist idalopirdine and the dopamine antagonist Rexulti (brexpiprazole), it could be a stable player in Alzheimer's.